Vertex Pharmaceuticals/$VRTX
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Vertex Pharmaceuticals
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex is focused on diversifying its portfolio through Casgevy (gene-editing therapy for beta thalassemia and sickle-cell disease), Journavx (non-opioid pain drug for moderate-to-severe acute pain), and Palsonify (for acromegaly). Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases, cell therapies to deliver a functional cure for type 1 diabetes, povetacicept (for IgA nephropathy).
- Ticker
- $VRTX
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 6,400
- Headquarters
- Boston, United States
- Website
- www.vrtx.com
VRTX Metrics
BasicAdvanced
$139B
35.23
$15.55
0.28
-
Price and volume
Market cap
$139B
Beta
0.28
52-week high
$568.67
52-week low
$412.27
Average daily volume
1.5M
Financial strength
Current ratio
2.337
Quick ratio
1.723
Long term debt to equity
0.262
Total debt to equity
0.31
Interest coverage (TTM)
108.07%
Profitability
EBITDA (TTM)
5,100.8
Gross margin (TTM)
54.94%
Net profit margin (TTM)
30.70%
Operating margin (TTM)
37.79%
Effective tax rate (TTM)
16.46%
Revenue per employee (TTM)
$2,020,000
Management effectiveness
Return on assets (TTM)
10.62%
Return on equity (TTM)
20.80%
Valuation
Price to earnings (TTM)
35.235
Price to revenue (TTM)
10.731
Price to book
6.64
Price to tangible book (TTM)
13.94
Price to free cash flow (TTM)
43.402
Free cash flow yield (TTM)
2.30%
Free cash flow per share (TTM)
12.624
Growth
Revenue change (TTM)
10.48%
Earnings per share change (TTM)
9.33%
3-year revenue growth (CAGR)
10.29%
10-year revenue growth (CAGR)
22.80%
3-year earnings per share growth (CAGR)
5.29%
10-year earnings per share growth (CAGR)
32.94%
What the Analysts think about VRTX
Analyst ratings (Buy, Hold, Sell) for Vertex Pharmaceuticals stock.
Analyst projections of the future price of Vertex Pharmaceuticals stock.
Bulls say / Bears say
Vertex raised its 2026 revenue guidance to $13.15–$13.25 billion after third-quarter revenue grew 12% to $3.44 billion, with cystic fibrosis demand and Alyftrek uptake driving growth. That gives the business strong near-term sales momentum. (Vertex Pharmaceuticals Newsroom)
Casgevy generated $99 million in third-quarter revenue, up 30% from the previous quarter and nearly sixfold year on year. Its expanded US approval for children aged two and over also widens the pool of potential patients. (Vertex Pharmaceuticals Newsroom)
The Crinetics acquisition has added rare endocrinology as a fourth commercial pillar, with Palsonify contributing $24 million in third-quarter revenue. This gives Vertex a new source of sales beyond cystic fibrosis and its earlier launches. (Vertex Pharmaceuticals Newsroom)
Cystic fibrosis remains the main earnings engine: it generated about $3.3 billion of Vertex’s $3.44 billion in third-quarter revenue. That leaves the company heavily exposed to any slowdown in its largest franchise. (The Motley Fool)
Journavx’s third-quarter sales of $58 million again came in below analyst expectations, despite prescription growth. The launch is growing, but its revenue contribution has yet to match expectations. (BioPharma Dive)
Povetacicept still needs FDA approval, and its commercial launch faces uncertainty: a petition has raised safety-monitoring concerns, similar drugs are already available, and scaling production of its monthly autoinjector could be difficult. Any of these issues could hinder a key part of Vertex’s planned kidney expansion. (BioPharma Dive)
Data summarised monthly by Lightyear AI. Last updated on 3 Nov 2026.
VRTX Financial Performance
Revenues and expenses
VRTX Earnings Performance
Company profitability
Upcoming events
No upcoming events
VRTX News
AllArticlesVideos
Funds containing VRTX
AllUSDEURGBP
Fund name | Fund size | $VRTX weighting |
|---|---|---|
iShares Nasdaq US Biotechnology£BTEK | $1.1B | 7.72% |
iShares Nasdaq US Biotechnology$BTEC | $1.1B | 7.72% |
Invesco Health Care S&P US Select Sector$XLVS | $552M | 2.20% |
Invesco Health Care S&P US Select Sector£XLVP | $552M | 2.20% |
iShares S&P 500 Health Care Sector€IUHE | €125M | 2.04% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.